[go: up one dir, main page]

AU2017376818A1 - Heparanase inhibitors and use thereof - Google Patents

Heparanase inhibitors and use thereof Download PDF

Info

Publication number
AU2017376818A1
AU2017376818A1 AU2017376818A AU2017376818A AU2017376818A1 AU 2017376818 A1 AU2017376818 A1 AU 2017376818A1 AU 2017376818 A AU2017376818 A AU 2017376818A AU 2017376818 A AU2017376818 A AU 2017376818A AU 2017376818 A1 AU2017376818 A1 AU 2017376818A1
Authority
AU
Australia
Prior art keywords
alkyl
groups
optionally substituted
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017376818A
Other languages
English (en)
Inventor
Martin Banwell
Edward Hammond
Colin Jackson
Keats NELMS
Brett SCHWARTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Therapeutics Pty Ltd
Original Assignee
Beta Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902346A external-priority patent/AU2017902346A0/en
Application filed by Beta Therapeutics Pty Ltd filed Critical Beta Therapeutics Pty Ltd
Publication of AU2017376818A1 publication Critical patent/AU2017376818A1/en
Priority to AU2022201731A priority Critical patent/AU2022201731B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017376818A 2016-12-13 2017-12-13 Heparanase inhibitors and use thereof Abandoned AU2017376818A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022201731A AU2022201731B2 (en) 2016-12-13 2022-03-11 Heparanase inhibitors and use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662433639P 2016-12-13 2016-12-13
US62/433,639 2016-12-13
AU2017902346 2017-06-20
AU2017902346A AU2017902346A0 (en) 2017-06-20 Methods of treating ocular disorders
PCT/AU2017/000271 WO2018107201A1 (fr) 2016-12-13 2017-12-13 Inhibiteurs d'héparanase et leur utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022201731A Division AU2022201731B2 (en) 2016-12-13 2022-03-11 Heparanase inhibitors and use thereof

Publications (1)

Publication Number Publication Date
AU2017376818A1 true AU2017376818A1 (en) 2019-07-11

Family

ID=67148292

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017376818A Abandoned AU2017376818A1 (en) 2016-12-13 2017-12-13 Heparanase inhibitors and use thereof
AU2022201731A Active AU2022201731B2 (en) 2016-12-13 2022-03-11 Heparanase inhibitors and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022201731A Active AU2022201731B2 (en) 2016-12-13 2022-03-11 Heparanase inhibitors and use thereof

Country Status (4)

Country Link
EP (1) EP3555071A4 (fr)
AU (2) AU2017376818A1 (fr)
IL (1) IL267243A (fr)
WO (1) WO2018107201A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020104842A1 (fr) * 2018-11-21 2020-05-28 The University Of The West Indies Composés et utilisations associées
CN118852197B (zh) * 2024-06-27 2025-09-05 常州康安生物科技有限公司 一种芹菜素衍生物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668787A (en) * 1985-12-20 1987-05-26 Ortho Pharmaceutical Corporation 5,6-dialkoxy-4-imino-2(1H)quinazolinone derivatives
EP0594877A1 (fr) * 1992-10-26 1994-05-04 National Science Council Dérivés d'imidazo(1,2-c)quinazoline comme antihypertensives et antidysuriques
GT199900185A (es) * 1998-11-06 2001-04-18 Novedosa pirimidin-4-enamina como fungicida.
EP1485380B1 (fr) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines inhibitrices des proteines kinases
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
RU2483074C2 (ru) * 2007-10-16 2013-05-27 Проджен Фармасьютикалз Лимитед Новые сульфатированные производные олигосахаридов

Also Published As

Publication number Publication date
WO2018107201A1 (fr) 2018-06-21
EP3555071A1 (fr) 2019-10-23
AU2022201731B2 (en) 2024-03-28
AU2022201731A1 (en) 2022-04-07
IL267243A (en) 2019-08-29
EP3555071A4 (fr) 2020-06-10

Similar Documents

Publication Publication Date Title
AU2014334554B2 (en) Selectively substituted quinoline compounds
ES2672530T3 (es) Amidas heterocíclicas como inhibidores de cinasas
JP2024517847A (ja) Ｒａｓ阻害剤
KR102268155B1 (ko) 테트라히드로피라졸로피리미딘 화합물
CA3159559A1 (fr) Inhibiteurs de ras
RU2707953C2 (ru) Производное пиридона, имеющее тетрагидропиранилметильную группу
AU2017376817B2 (en) Heparanase inhibitors and use thereof
US20230050653A1 (en) Rock inhibitor and preparation method therefor and use thereof
EA037112B1 (ru) Ингибиторы tgf-
JP2017001991A (ja) 新規ベンズオキサゾロン化合物
KR20230005188A (ko) 피리도피리미디논 유도체 및 이의 아릴 탄화수소 수용체 조절제로서의 용도
TW202122382A (zh) 乙內醯脲衍生物
AU2022201731B2 (en) Heparanase inhibitors and use thereof
JP2024513538A (ja) Ｐａｒｐ阻害剤としての置換融合二環式化合物及びその使用
JP2021525810A (ja) トリプトファン異化のモジュレーター
JP2019001715A (ja) 三環性化合物
CA2975372C (fr) Agent prophylactique et/ou therapeutique destine a des maladies immunitaires
EP3740493A1 (fr) Inhibteurs de l'indoléamine 2,3-dioxygénase et/ou du tryptophane dioxygénase
CA3103068C (fr) Derives de triazolotriazine en tant qu'antagonistes du recepteur a2a
US20250059174A1 (en) Pharmaceutical Compounds and Compositions as C-Kit Kinase Inhibitors
US20250034138A1 (en) Compounds and Compositions as C-Kit Kinase Inhibitors
US11787783B2 (en) Heparanase inhibitors and use thereof
KR20240093769A (ko) 암 및 섬유성 질환의 치료를 위한 ddr1 및 ddr2 억제제
RU2818954C1 (ru) Производные пиридопиримидинона и их использование в качестве модуляторов рецептора ароматических углеводородов
US20250304600A1 (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted